Table 2: Trends in antimicrobial consumption at university hospital of Sahloul, Sousse, Tunisia, 2001 to 2015.

Antibiotic Antibiotic Consumption (DDD/1000 patient-days) by Year Correlation
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 r p R2
CAZ 3.8 3.2 2.8 1 3 6 4 3.6 3 3.5 4 7 3.5 7 5.5 0.574 0.025 0.330
IMP 12.9 14.5 12.6 13 22 27 27.5 25.6 19 24 25.5 23 29 27 32.5 0.816 <103 0.665
AN 9 9 8 4 33 10 11 8 6.6 7.3 9 8 8.5 10 7 -0.17 0.539 0.030
GM 43.5 45.2 42.5 14 33 27 28 24 23 19.5 19 16 19 23 23.5 0.71 0.003 0.502
LVX 0 0.1 2 1 3.5 5 4.5 2 4 3 2 3 4.5 3.5 3.2 0.56 0.030 0.314
CIP 17.9 23 22 11 34.5 37 34 36.5 35.7 39 33 44.5 31.5 41 17 0.46 0.085 0.211
FOS 1.3 3.4 4.5 2 5 2.6 4 7 6.5 6.3 7 5 10.5 8 8 0.834 <103 0.696
SXT 7.6 5.8 5 1.5 4 3.5 2 4.5 3.5 3 3 2.5 3 4 6 -0.3 0.280 0.089
RA 53 53.8 53 23 23 45 46 38.6 40 24.5 35.5 41 44 49 50 -0.05 0.865 0.002
COL 0.1 0.1 0.1 0.1 0.1 0.1 0.3 0.2 0.3 0.2 0.3 1.3 1.3 2 2 0.821 <103 0.675

DDD: defined daily dose; r: Spearman's rho; p: p-value * Statistically significant association (r > 0.72, P < 0.05); CI, 95% confidence interval
CAZ: Ceftazidime, IMP: Imipenem, AN: Amikacin, GM: Gentamicin, LVX: Levofloxacin, CIP: Ciprofloxacin, FOS: Fosfomycin, SXT: Sulphamethoxazole / trimethoprim, RA: Rifampicin,, COL: Colistin.